This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why the Earnings Streak Will Continue for Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) can be a harbinger of out performance and a signal for a strong earnings profile on the back of its favorable Zacks rank and earnings ESP in the positive territory.
Inovalon Holdings' ONE Platform Chosen by UnitedHealthcare
by Zacks Equity Research
Inovalon Holding (INOV) will be able to expand in the population health management space through the selection of its proprietary ONE Platform by UnitedHealthcare.
Fresenius Medical Opens Manufacturing Plant in Malaysia
by Zacks Equity Research
Fresenius Medical's (FMS) Malaysian plant will strengthen the company's presence in the rapidly-growing market.
Amedisys Rides High on Strong Prospects Amid Margin Woes
by Zacks Equity Research
Strength in Hospice and Personal Care businesses are offsetting the weakness in Amedisys' (AMED) Home Health Medicare business.
Medtronic's IN.PACT Admiral Approval in Japan Boosts APV Arm
by Zacks Equity Research
Medtronic's (MDT) receipt of Japanese regulatory approval for IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.
IDEXX Laboratories Rides High on Strong CAG, Global Growth
by Zacks Equity Research
IDEXX (IDXX) rides high on balanced segmental growth with significant contributions from the Companion Animal Group business. Moreover, strong fundamentals buoy optimism.
Medtronic Launches StealthStation Technology, Expands in ENT
by Zacks Equity Research
Medtronic (MDT) recently launched StealthStation ENT, which enables surgeons to gain better visualization.
Centene's Fidelis Care Buyout to Expand Presence in New York
by Zacks Equity Research
Centene's (CNC) acquisition of Fidelis Care for $3.75 billion for expanding in New York, is expected to impact Centene's top line and bottom line positively.
5 Discounted MedTech Stocks for a Healthy Portfolio
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these five MedTech stocks stand out as the most suitable value picks.
Universal Health (UHS) Grows on Buyouts, Expenses a Drag
by Zacks Equity Research
Despite solid revenue growth backed by inorganic strategies, Universal Health's (UHS) rising level of debt and expenses continue to weigh on margins.
Top Ranked Growth Stocks to Buy for September 11th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, September 11th:
Amedisys to Buy Intercity Home Care, Boosts Personal Care Arm
by Zacks Equity Research
Amedisys (AMED) to strengthen its position in Personal Care business in Massachusetts with this recently signed acquisition deal.
3 Excellent Value Picks as Political Chaos Grips MedTech
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these three MedTech stocks stand out as the most suitable value picks.
Ensign Group's Inorganic Growth Impresses, Debt Level Hurts
by Zacks Equity Research
Ensign Group's (ENSG) top line rises on inorganic and organic growth. Its financial health also impresses. However high level of costs and debts bother.
Molina Healthcare's Top Line Grows on Membership, Debts Hurt
by Zacks Equity Research
Molina Healthcare's (MOH) top line benefits from inorganic growth and membership. However, rising level of debt and expenses hurt margins.
WellCare Health Partners Mission Health to Improve Offerings
by Zacks Equity Research
WellCare Health Plans, Inc's (WCG) subsidiary, Wellcare of North Carolina recently entered into an agreement with Mission Health to provide better Medicaid and Medicare services in North Carolina.
Centene (CNC) Poised to Grow on Buyouts, High Debt Bothers
by Zacks Equity Research
Centene's (CNC) accretive acquisitions backed by solid financials add to its top line. However, high debt and rising expenses hurt margins.
Amedisys (AMED) Up 3.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Amedisys (AMED) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Chemed (CHE) is a Suitable Growth Pick for Now
by Zacks Equity Research
Banking on favorable Net Margin and ROE, Chemed (CHE) stands out as one of the most suitable growth stocks.
IDEXX Laboratories (IDXX), Great Growth Pick: Here's Why
by Zacks Equity Research
Banking on a number of favorable metrics, IDEXX Laboratories (IDXX) stands out as one of the most suitable growth stock.
Is Amedisys (AMED) a Great Value Stock for Your Portfolio?
by Zacks Equity Research
Banking on a number of favorable metrics, Amedisys (AMED) stands out as one of the most suitable value stock.
Here's Why Masimo (MASI) is a Suitable Value Pick for Now
by Zacks Equity Research
Masimo (MASI) seems to be a solid value pick with favorable P/E ratio and P/FCF ratio compared with its broader industry.
Here's Why Investors Should Buy Amedisys (AMED) Right Now
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.
Tabula Rasa Healthcare (TRHC) Catches Eye: Stock Up 9.5%
by Zacks Equity Research
Tabula Rasa Healthcare, Inc. (TRHC) shares rose around 10% in the last trading session.
Aetna's (AET) $1 Billion Notes Due 2047 Rated By A.M Best
by Zacks Equity Research
Rating Giant A.M Bests assigned a Long-Term Issue Credit Rating of "bbb" to Aetna's (AET) $1 billion, 3.875% senior notes due to mature on Aug 15, 2047.